CL2023000659A1 - Péptido que se une al mhc - Google Patents
Péptido que se une al mhcInfo
- Publication number
- CL2023000659A1 CL2023000659A1 CL2023000659A CL2023000659A CL2023000659A1 CL 2023000659 A1 CL2023000659 A1 CL 2023000659A1 CL 2023000659 A CL2023000659 A CL 2023000659A CL 2023000659 A CL2023000659 A CL 2023000659A CL 2023000659 A1 CL2023000659 A1 CL 2023000659A1
- Authority
- CL
- Chile
- Prior art keywords
- peptide
- mhc
- binds
- cells
- tumors
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La solicitud se relaciona con un péptido de secuencia SEQ ID N ° 41 expresado en tumores, que tiene la capacidad de unirse a una molécula del complejo principal de histocompatibilidad (MHC) humano de clase I y en el que dicho péptido es capaz de estimular células T CD4 y/o células T CD8 útiles en inmunoterapia contra el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862732863P | 2018-09-18 | 2018-09-18 | |
DE102018122900 | 2018-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023000659A1 true CL2023000659A1 (es) | 2023-08-18 |
Family
ID=68062920
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000653A CL2021000653A1 (es) | 2018-09-18 | 2021-03-17 | Inmunoterapia con péptidos restringidos a a*01 y una combinación de péptidos contra el cáncer y métodos relacionados. |
CL2023000659A CL2023000659A1 (es) | 2018-09-18 | 2023-03-08 | Péptido que se une al mhc |
CL2023000658A CL2023000658A1 (es) | 2018-09-18 | 2023-03-08 | Péptido que se une al mhc |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000653A CL2021000653A1 (es) | 2018-09-18 | 2021-03-17 | Inmunoterapia con péptidos restringidos a a*01 y una combinación de péptidos contra el cáncer y métodos relacionados. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023000658A CL2023000658A1 (es) | 2018-09-18 | 2023-03-08 | Péptido que se une al mhc |
Country Status (19)
Country | Link |
---|---|
US (8) | US10954281B2 (es) |
EP (1) | EP3852787A1 (es) |
JP (1) | JP7476174B2 (es) |
KR (1) | KR20210063320A (es) |
CN (1) | CN113164569A (es) |
AU (1) | AU2019342860A1 (es) |
BR (1) | BR112021003511A2 (es) |
CA (1) | CA3108582A1 (es) |
CL (3) | CL2021000653A1 (es) |
CO (1) | CO2021003404A2 (es) |
CR (1) | CR20210141A (es) |
IL (2) | IL309715A (es) |
MA (1) | MA53644A (es) |
MX (1) | MX2021003089A (es) |
PE (1) | PE20211643A1 (es) |
PH (1) | PH12021550581A1 (es) |
SG (1) | SG11202101926TA (es) |
TW (1) | TW202024121A (es) |
WO (1) | WO2020058360A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
MA49122A (fr) | 2017-04-10 | 2021-03-24 | Immatics Biotechnologies Gmbh | Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse |
WO2021188743A2 (en) * | 2020-03-20 | 2021-09-23 | Neo7Logix, Llc | Precision-based immuno-molecular augmentation (pbima) computerized system, method and therapeutic vaccine |
JP2023521219A (ja) * | 2020-04-14 | 2023-05-23 | ウニヴェルシテ ド モントリオール | 急性骨髄性白血病(aml)に対する新規の腫瘍特異的抗原及びそれらの使用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
NO794196L (no) | 1978-12-22 | 1980-06-24 | Biogen Nv | Fremgangsmaate ved fremstilling av et rekombinert dna molekyl |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
WO1997026328A1 (en) | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
JP2004503213A (ja) | 2000-03-27 | 2004-02-05 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 1本鎖クラスi主要組織適合性複合体、それをコードする構築物およびそれを生成する方法 |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
CN1464790A (zh) | 2000-06-05 | 2003-12-31 | 苏诺尔分子公司 | T细胞受体融合物及共轭物以及其使用方法 |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
WO2003070752A2 (en) | 2002-02-20 | 2003-08-28 | Dyax Corporation | Mhc-peptide complex binding ligands |
NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
ATE432290T1 (de) | 2002-11-09 | 2009-06-15 | Immunocore Ltd | T ZELL REZEPTOR ßDISPLAYß |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
EP1806359B1 (en) | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
WO2012056407A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
US20190292535A1 (en) | 2012-11-08 | 2019-09-26 | Roche Diagnostics Operations, Inc. | Nucleic acids encoding chimeric polypeptides for library screening |
EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
US11175289B2 (en) * | 2016-11-16 | 2021-11-16 | Lei Han | Application of TRPM8 protein, related peptide fragment and their antibodies |
-
2019
- 2019-09-16 TW TW108133156A patent/TW202024121A/zh unknown
- 2019-09-18 IL IL309715A patent/IL309715A/en unknown
- 2019-09-18 KR KR1020217004770A patent/KR20210063320A/ko unknown
- 2019-09-18 BR BR112021003511-7A patent/BR112021003511A2/pt unknown
- 2019-09-18 MA MA053644A patent/MA53644A/fr unknown
- 2019-09-18 CN CN201980060335.3A patent/CN113164569A/zh active Pending
- 2019-09-18 JP JP2021514549A patent/JP7476174B2/ja active Active
- 2019-09-18 EP EP19773780.2A patent/EP3852787A1/en active Pending
- 2019-09-18 WO PCT/EP2019/075065 patent/WO2020058360A1/en unknown
- 2019-09-18 CR CR20210141A patent/CR20210141A/es unknown
- 2019-09-18 CA CA3108582A patent/CA3108582A1/en active Pending
- 2019-09-18 AU AU2019342860A patent/AU2019342860A1/en active Pending
- 2019-09-18 MX MX2021003089A patent/MX2021003089A/es unknown
- 2019-09-18 SG SG11202101926TA patent/SG11202101926TA/en unknown
- 2019-09-18 PE PE2021000319A patent/PE20211643A1/es unknown
- 2019-09-18 US US16/575,250 patent/US10954281B2/en active Active
-
2020
- 2020-06-30 US US16/917,141 patent/US10899813B2/en active Active
- 2020-06-30 US US16/917,040 patent/US10870685B2/en active Active
- 2020-06-30 US US16/917,176 patent/US11001617B2/en active Active
- 2020-06-30 US US16/917,230 patent/US10899814B2/en active Active
- 2020-06-30 US US16/916,833 patent/US10899812B2/en active Active
-
2021
- 2021-03-16 CO CONC2021/0003404A patent/CO2021003404A2/es unknown
- 2021-03-16 PH PH12021550581A patent/PH12021550581A1/en unknown
- 2021-03-17 IL IL281596A patent/IL281596A/en unknown
- 2021-03-17 CL CL2021000653A patent/CL2021000653A1/es unknown
- 2021-04-13 US US17/229,592 patent/US11142556B2/en active Active
- 2021-09-14 US US17/474,894 patent/US20220009982A1/en active Pending
-
2023
- 2023-03-08 CL CL2023000659A patent/CL2023000659A1/es unknown
- 2023-03-08 CL CL2023000658A patent/CL2023000658A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000657A1 (es) | Péptido que se une al mhc | |
CL2021001744A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324) | |
CL2023000659A1 (es) | Péptido que se une al mhc | |
PE20181799A1 (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer microcitico de pulmon y otros tipos de cancer | |
CL2018003348A1 (es) | Péptidos y combinación de péptidos y andamiajes novedosos para su uso en inmunoterapia contra carninoma de células renales (rcc) y otros canceres. (divisional solicitud 201702448) | |
PE20181800A1 (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer de mama y otros tipos de cancer | |
CL2019003312A1 (es) | Nuevos péptidos (seq id no:122) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer.(divisional solicitud 201800124) | |
ZA202306640B (en) | T cell receptors | |
PE20181923A1 (es) | Neoantigenos y metodos de su uso | |
CO2018004865A2 (es) | Péptidos y combinaciones de péptidos para inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
PE20190335A1 (es) | Receptores de celulas t | |
CL2019002943A1 (es) | Nuevos péptidos y combinación para el uso en la inmunoterapia contra varios tipo de cáncer. divisional solicitud 201801533) | |
PE20181824A1 (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pulmon amicrocitico y otros tipos de cancer | |
EA201992536A1 (ru) | Tcr и пептиды | |
CL2018002648A1 (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
ECSP17027870A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer | |
MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
MX2019012360A (es) | Composiciones y metodos mejorados de celulas t. | |
CL2017003361A1 (es) | Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres | |
PE20160950A1 (es) | Biomarcadores de cancer y usos de los mismos | |
PE20190203A1 (es) | Nuevos peptidos y nueva combinacion de peptidos como dianas y para el uso en la inmunoterapia contra el cancer de vesicula biliar y el colangiocarcinoma, asi como otros tipos de cancer | |
CL2019003425A1 (es) | Nuevos péptidos (seq id n°42), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
CR20220115A (es) | PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522) | |
PE20191617A1 (es) | Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer | |
BR112016002572A2 (pt) | peptídeos |